Úspěšnost a bezpečnost léčby chronické hepatitidy C u hemofiliků.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F05%3A%230000001" target="_blank" >RIV/65269705:_____/05:#0000001 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens.

Popis výsledku v původním jazyce

Twelve haemophiliacs with chronic hepatitis C, all infected with genotype 1b, were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. Sustained virologic response was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy premat

Název v anglickém jazyce

Efficacy and safety of chronic hepatitis C treatment in haemophilic patiens.

Popis výsledku anglicky

Twelve haemophiliacs with chronic hepatitis C, all infected with genotype 1b, were treated with interferon-alfa monotherapy, 21 patients with interferon-alfa and ribavirin, and 3 patients with pegylated interferon and ribavirin, all for 48 weeks. Sustained virologic response was not achieved in any of 12 patients treated with interferon-alfa alone. Combination therapy with interferon-alfa and ribavirin was associated with better results: 4/10 (40%) patients still untreated with interferon-alfa, 2/4 (50%) relapsers, and 2/7 (29%) non-responders to previous interferon-alfa monotherapy achieved sustained virologic responses. Combination therapy with pegylated interferon and ribavirin has been used in 3 patients. Sustained response was achieved in one patient who had relapsed after treatment with interferon-alfa and ribavirin and in 1 of 2 non-responders to this combination therapy. There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy premat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NI7484" target="_blank" >NI7484: Závislost setrvalé virologické odpovědi na virové kinetice v počátcích léčby chronické hepatitidy C kombinací alfa-interferonu, nebo pegylovaného interferonu, a ribavirinu.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Hepato-Gastroenterology

ISSN

0172-6390

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

65

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

4

Strana od-do

1541-1544

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—